impact of a biophoton therapy on patients with brain disorders

Conditions: Brain Disorders - Alzheimer's Disease, Dementia, Parkinson's Disease, Traumatic Brain Injury

Summary: previous clinical studies revealed that the newly developed biophoton therapy has been safe and effective in treating patients with alzheimer's disease, dementia, stroke, traumatic brain injury, or parkinson's disease. the current study is to confirm the previous clinical observation by conducting as a randomized, triple-blinded, placebo-controlled prospective intervention clinical research. about 80 patients with brain disorder (alzheimer's disease, dementia, stroke, traumatic brain injury, parkinson's disease) will participate in the intervention clinical study at the tesla medbed center located in butler, pa.

the participant will live in the hotel-like research center for 4 weeks, or 6 weeks if the participants are randomly placed in a placebo group. the initial 2 weeks of participation is triple blinded to record the placebo effects, as each set of the study device is labelled with a unique code for use by only one participant. the change of the placebo device to the treatment device will be performed by the study device management team staff who will not inform the study participant nor study research staff who involve study data collection. each participant assigned to the control group will be treated with 14 placebo devices under the bed plus two placebo devices to place in bed on each side of the head. each participant assigned to the treatment group will receive 14 biophoton generator devices under the bed plus two biophoton generators to place in bed on each side of the head. each participant will use the treatment or control device for at least 8 hours every night for the first 2 weeks during sleep. during the day, participants are welcome to move around the facility, visit people or places. at the end of the first 2 weeks, the study participants will be advised whether she/he will be continually in a treatment group for 2 more weeks or be switched from a placebo group to a treatment group for 4 more weeks. each participant will be guided by study team staff on their assigned testing day to answer the standard sf-36 questionnaires (sf-36) for measuring life quality, cognitive improvement questionnaires, physician performed neurologic examination, bio-well energy test, the electroencephalography (eeg) test, blood flow test, and brain biophoton test, respectively at the baseline, 2 and 4 weeks after the study treatment.

Eligibility criteria:
inclusion criteria: * must meet conditions for approval. * must be 18-years or older and stay in a hotel. * must have a caregiver willing to support the participant's full involvement in the study. • the caregiver can assist in completing all study surveys. * can provide informed consent or can be assisted by caregiver. * can provide a clinical diagnosis of a brain disorder. * can complete all study procedures during the study. * must be fluent in english (or the caregiver can fully translate). * women of childbearing age must provide results of a pregnancy test in order to participate. exclusion criteria: * any untreated mental illnesses, that would affect study participation. this will be judged by the caregiver, or by the clinical study medical expert. * someone that relies on a ventilator. * someone who has a deep brain stimulator, pacemaker, or any implanted electronic devices. * co-morbid conditions that would interfere with study activities or response to treatment, which may include severe chronic pulmonary disease, history of uncontrolled seizures, acute or chronic infectious illness, severe diabetes, kidney failure, or any end-of-life prognosis. * is participating in another investigational drug or device trial. * has an active infectious disease, such as covid-19. * pregnant women.

Keywords: alzheimer's disease, and/or dementia, and/or parkinson's disease, and/or traumatic brain injury, and/or